ArticleOncology letters2018
Programmed death-ligand 1 positivity can predict improved survival and a lower risk of brain metastasis in patients with resectable small cell lung cancer.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.Cells · 2020Pooled it
- Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Development and validation of a nomogram for the prediction of brain metastases in small cell lung cancer.The clinical respiratory journal · 2023Article
- Immune related biomarkers for cancer metastasis to the brain.Experimental hematology & oncology · 2022Review
- The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer.Translational lung cancer research · 2021Article
- Association between clinicopathological features and prognosis significance of PD-L1 expression in small cell lung cancer patients: a systemic review and meta-analysis.Translational cancer research · 2020Article
- PD-L1 Predicts Poor Prognosis in Surgically Resected Limited Stage Small-Cell Lung Cancer.Cancer management and research · 2020Article
- Characterization of PD-L1 protein expression and CD8Translational lung cancer research · 2019Article
- Are there any theranostic biomarkers in small cell lung carcinoma?Journal of thoracic disease · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to investigate the expression of programmed death-ligand 1 (PD-L1) in resectable small cell lung cancer (SCLC) and investigate its predictive value for survival and brain metastasis (BM). Postoperative SCLC specimens were immunostained with the SP142 antibody against PD-L1. Positive PD-L1 expression was defined as PD-L1 expression in ≥5% of tumor cells. A total of 80 patients were recruited between January 2010 and December 2012. PD-L1 was expressed in 65.0% (52/80) of all patients and 59.3% (16/27) of patients with BM. The median survival time (MST) was longer in the PD-L1(+) group (46.4 vs. 28.5 months, P=0.002). There was no significant difference in the MST between patients with PD-L1(+) or (-) BM (P=0.55). The 3-year risk of BM in the PD-L1(+) group was lower than that in the PD-L1(-) group (24.1 vs. 48.4%, P=0.046). PD-L1 was an independent factor for overall survival (OS) [hazard ratio (HR)=0.485, P=0.011] and BM (HR=0.335, P=0.024). The present study concludes that PD-L1 is commonly expressed in SCLC and is associated with OS and BM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.